Zobrazeno 1 - 10
of 356
pro vyhledávání: ''
Autor:
Jing-Jing Jiang, Masaaki Murakami, Ikuma Nakagawa, Shuhei Shimoyama, Shintaro Hojyo, Osamu Ohara, Tatsuya Atsumi, Mona Uchida, Isao Matsumoto, John A. Chiorini, Mitsutoshi Ota, Yuki Tanaka, Rie Hasebe, Daisuke Kamimura, Yoshinori Hasegawa
Publikováno v:
Int Immunol
Sjögren’s syndrome (SS) is an autoimmune disease characterized by inflammation with lymphoid infiltration and destruction of the salivary glands. Although many genome-wide association studies have revealed disease-associated risk alleles, the func
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose com
Autor:
Yasue Kimura, Eiji Oki, Yoshiaki Fujimoto, Masahito Kotaka, Koji Ando, Hiroyuki Kitao, Yuji Miyamoto, Masaki Mori, Ryota Nakanishi, Shichao Qiu, Yoshihiko Maehara, Mototsugu Shimokawa, Akitaka Makiyama
Publikováno v:
Cancer Science
Trifluridine/tipiracil (FTD/TPI) is an orally administrated anticancer drug with efficacy validated for patients with metastatic colorectal cancer (mCRC) or gastric cancer. FTD, a key component of FTD/TPI, exerts antitumor effects via its incorporati
Publikováno v:
Inflammation. 44:1803-1814
Rheumatoid arthritis (RA) remains the most common inflammatory arthritis and a major cause of disability. This study investigated the mechanism of MLL3 in fibroblast-like synoviocyte (FLS) apoptosis and inflammatory factor secretion in RA. Expression
Autor:
James Yu, Estrella Carballido, Richard D. Kim, Maria Elena Martinez, Iman Imanirad, Michael J. Schell, Jun-Min Zhou, Elaine Tan, Dae-Won Kim, Rutika Mehta, Jonathan R. Strosberg
Publikováno v:
Br J Cancer
BACKGROUND: MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy. Recent data suggest that ibrutinib may enhance the anti-tumour activity of anti-PD-1 immunotherapy. In this study, we evaluated the safety and efficac
Autor:
Manjunath Nookala, Vikram Gota, Ashwin Karanam, Anand P. Patil, Navin Goyal, Ashish Singh, Murari Gurjar, Avinash Bonda, Yogesh Kembhavi, Sudeep Gupta, Bharati Shriyan
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 9, Pp 3068-3076 (2021)
Cancer Medicine, Vol 10, Iss 9, Pp 3068-3076 (2021)
Background Paclitaxel is dosed according to body surface area (BSA) but there is scant information on actual drug exposure in overweight and obese patients. Methods Early breast cancer patients receiving paclitaxel at 175 mg/m2 every 3 weeks, in two
Autor:
Larry Z. Zheng, Jessica Yancey, Linda Ding, Jennifer K. Yates, Kriti Mittal, Yang Zong, Zhong Jiang, Jesse N. Aronowitz, Thomas J. Fitzgerald
Publikováno v:
American Journal of Clinical Oncology. 44:175-180
Introduction Hematuria can be a distressing and debilitating complication of urothelial carcinoma (UC) of the kidney for patients who are not candidates for surgery or ureteroscopic ablation. We retrospectively assessed the efficacy, tolerability, an
Autor:
Yukio Miki, Kohei Kotani, Kanako Yoshida, Kenjiro Kimura, Naoshi Odagiri, Sawako Uchida-Kobayashi, Akihiro Tamori, Hiroko Ikenaga, Shoji Kubo, Atsushi Hagihara, Ken Kageyama, Masaru Enomoto, Norifumi Kawada, Akira Yamamoto, Hideki Fujii
Publikováno v:
Oncology. 99(3):186-191
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-relate
Autor:
Jos H. Beijnen, Alwin D. R. Huitema, Philip C. Schouten, Sabine C. Linn, Jan H.M. Schellens, Katarzyna Jóźwiak, Serena Marchetti, Gwen M. H. E. Dackus, Jill J.J. Geenen, Gabe S. Sonke, Dick Pluim
Publikováno v:
International Journal of Cancer
Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olapa
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1623-1633 (2021)
Cancer Medicine
Cancer Medicine
Background Metabolomics is the newest ‐omics methodology and allows for a functional snapshot of the biochemical activity and cellular state. The goal of this study is to characterize metabolomic profiles associated with cancer‐related fatigue, a